| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.18 | 9e-07 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.19 | 9e-07 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.14 | 8e-06 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.15 | 9e-06 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.14 | 4e-05 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.14 | 8e-05 |